Literature DB >> 15958073

Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss.

K Kobayashi1, M Ishii, M Shiina, Y Ueno, Y Kondo, A Kanno, Y Miyazaki, T Yamamoto, T Kobayashi, H Niitsuma, Y Kikumoto, H Takizawa, T Shimosegawa.   

Abstract

Differences in cytotoxic T lymphocyte activity in hepatitis C virus infection may account for the outcome of interferon monotherapy. To investigate this hypothesis, we analysed the response of peripheral CD8(+) T cells that recognized epitopes presented by HLA-A*2402. We synthesized HLA/beta2-microglobulin/peptide complexes using two epitopes. Production of interferon-gamma by CD8(+) T cells in response to plastic-bound monomeric HLA/peptide complex was observed frequently in sustained virus responders (SVR) (n = 13) against all the peptides, NS31296-1304 (the percentage of responding patients, 61.5%) and core 129-137 (53.8%), while no interferon-gamma production was observed in non-responders (NR) (n = 13) for any of the peptides. Tetramer-staining showed the presence of CD8(+) T cells specific for all the peptides except NS31296-1304 in two SVR at the end of interferon monotherapy, although hardly any such cells were found in four NR. Specific killing was observed against peptides NS31296-1304 (3/4) and core 129-137 (1/4) in sustained responders but none in non-responders. These results suggest that the responses of cytotoxic T lymphocytes (CTLs) were induced during interferon therapy in these patients and that interferon-gamma production by CD8(+) T lymphocytes against HCV NS31296-1304 and core 129-137 are well maintained in patients with SVR compared with those with NR. These findings emphasize the importance of the CD8(+) T cell response in controlling HCV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958073      PMCID: PMC1809409          DOI: 10.1111/j.1365-2249.2005.02018.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion.

Authors:  I M Belyakov; J Wang; R Koka; J D Ahlers; J T Snyder; R Tse; J Cox; J S Gibbs; D H Margulies; J A Berzofsky
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

2.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia.

Authors:  Y Sobao; K Sugi; H Tomiyama; S Saito; S Fujiyama; M Morimoto; S Hasuike; H Tsubouchi; K Tanaka; M Takiguch
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

4.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.

Authors:  F Lechner; N H Gruener; S Urbani; J Uggeri; T Santantonio; A R Kammer; A Cerny; R Phillips; C Ferrari; G R Pape; P Klenerman
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

5.  Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein.

Authors:  Stephan Gehring; Stephen H Gregory; Noriyoshi Kuzushita; Jack R Wands
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

6.  Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection.

Authors:  M Cucchiarini; A R Kammer; B Grabscheid; H M Diepolder; T J Gerlach; N Grüner; T Santantonio; J Reichen; G R Pape; A Cerny
Journal:  Cell Immunol       Date:  2000-08-01       Impact factor: 4.868

7.  Antiviral CD8+ T cell responses in neonatal mice: susceptibility to polyoma virus-induced tumors is associated with lack of cytotoxic function by viral antigen-specific T cells.

Authors:  J M Moser; J D Altman; A E Lukacher
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

8.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

Review 10.  Assessing CD8 T cell number and dysfunction in the presence of antigen.

Authors:  R M Welsh
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

View more
  2 in total

1.  Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients.

Authors:  Masaaki Shiina; Koju Kobayashi; Tomoo Kobayashi; Yasuteru Kondo; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

2.  Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b.

Authors:  Dong-Won Kim; Seoung-Ae Lee; Hong Kim; You-Sub Won; Bum-Joon Kim
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.